Trial Search Results
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Stanford is currently not accepting patients for this trial.
Collaborator: National Comprehensive Cancer Network
- Drug: Vorinostat
- Procedure: Radiation Therapy
- All patients age 18 years and older with histologically proven non-small cell lung
cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior
surgery or radiation is allowed as long as the target metastatic lesion(s) has not
been treated with previous radiation.
- Adequate organ function (section 3.1.10).
- ECOG performance status 0-2.
- Life expectancy of >=12 weeks.
- Systemic chemotherapy washout period >=7 days.
Patients who have previously been treated with whole brain irradiation, pediatric patients
(age <18), pregnant women, and patients who are unable to give informed consent.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study